Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-07-18
2006-07-18
Badio, Barbara P. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S824000
Reexamination Certificate
active
07078396
ABSTRACT:
A method of treating a disorder related to a high cholesterol concentration, comprising administering to a subject in need thereof a compound of formula (I):Also disclosed are methods, kits, combinations, and compositions for treating a disorder in a subject where an activator of liver X alpha is indicated, such as in, for example, treating a high cholesterol disease.
REFERENCES:
patent: 2698853 (1955-01-01), Wildi
patent: 3784598 (1974-01-01), Iseli et al.
patent: 3887545 (1975-06-01), Iacobelli et al.
patent: 3925480 (1975-12-01), Thal et al.
patent: 3963765 (1976-06-01), Mazur et al.
patent: 4006172 (1977-02-01), Salmond
patent: 4125544 (1978-11-01), Dygos
patent: 4193930 (1980-03-01), Chorvat
patent: 4304726 (1981-12-01), Arakawa et al.
patent: 4639420 (1987-01-01), Schaffner
patent: 4917898 (1990-04-01), Angelico et al.
patent: 5332857 (1994-07-01), McCarthy et al.
patent: 5362891 (1994-11-01), Bonaldi et al.
patent: 5424463 (1995-06-01), Lardy et al.
patent: 5466815 (1995-11-01), Enhsen et al.
patent: 5482935 (1996-01-01), Adelman et al.
patent: 5508453 (1996-04-01), Arosio et al.
patent: 5562910 (1996-10-01), Daynes et al.
patent: 5583239 (1996-12-01), Regen
patent: 5639744 (1997-06-01), Marchi et al.
patent: 6060465 (2000-05-01), Miljkovic et al.
patent: 6369247 (2002-04-01), Miller et al.
patent: 6465258 (2002-10-01), Shan et al.
patent: 6639078 (2003-10-01), Haffner et al.
patent: 6645955 (2003-11-01), Liao et al.
patent: 2002/0107233 (2002-08-01), Liao et al.
patent: 2002/0193357 (2002-12-01), Song et al.
patent: 2004/0014734 (2004-01-01), Song et al.
patent: 123 286388 (1995-03-01), None
patent: 110729 (1995-03-01), None
patent: 0 562 849 (1993-09-01), None
patent: 1 405 818 (1975-09-01), None
patent: 2 009 180 (1979-06-01), None
patent: 94/02503 (1994-02-01), None
patent: 98/32444 (1998-07-01), None
patent: 00/66611 (2000-11-01), None
patent: 02/062302 (2002-08-01), None
patent: 02/090375 (2002-11-01), None
patent: 03/039480 (2003-05-01), None
patent: 03/086303 (2003-10-01), None
Cohen-Solal et al., “Effects of hyodeoxycholic acid and alpha-hyocholic acid, two 6 alpha-hydroxylated bile acids, on cholesterol and bile acid metabolism in the hamster.” Biochimica et biophysica Acta, vol. 1257, pp. 189-197, 1995.
Angelico et al., Dissolution of Human Cholesterol Gallstones in Bile Salt/Lecithin Mixtures: Effect of Bile Salt Hydrophobicity and Various pHs, Scandinavin Journal of Gasteroenterology 30:1178-1185, 1195.
Bleau et al. “Cholesterol sulfate. I. Occurrence and possible biological function as an amphipathic lipid in the membrane of the human erythrocyte.”Biochimica et Biophysica Acta, vol. 352(1), pp. 1-9, (1974).
Ajay Chawla et al., “Nuclear Receptors and Lipid Physiology: Opening the X-Files”,Science, vol. 294, pp. 1866-1870 (Nov. 30, 2001).
Cohen et al., “The preparation of bile acid amides and oxazolines. II. The synthesis of the amides and oxazolines of ursdeoxycholic acid, deoxycholic acid, hyodeoxycholic acid and cholic acid”,Steroids, vol. 40, No. 6, pp. 701-711 (Dec. 1982).
Coleman et al., “Synthesis and Characterization of Novel Analogs of Conjugated Bile Acids Containing Reversed Amide Bonds”, Journal of Lipid Research 36:901-910, 1995.
Dusza et al., “A Fusion Method for Preparation of Steroid Sulfates,” Steroids p. 317-323 (1985).
Dusza et al., “The Preparation of Estradiol-17β Sulfates with Triethylamine-Sulfur Trioxide,” Steroids p. 303-315 (1985).
Adomo Fini et al., “Quantitative Structure-Antimicrobial Activity Relationship in 5β-Cholanyl-24-benzylamine Derivatives”,Journal of Pharmaceutical Sciences, vol. 79, No. 7, pp. 603-605 (Jul. 1990).
Charles Freudenreich, et al., “Design of Inhibitors from the Three-Dimensional Structure of Alcohol Dehydrogenase, Chemical Synthesis and Enzymatic Properties”,J. Am. Chem. Soc., pp. 3344-3353, (1984).
Xuan Fu et al., “27-Hydroxycholesterol Is an Endogenous Ligand for Liver X Receptor in Choleserol-loaded Cells”,The Journal of Biological Chemistry, Vo. 276, No. 42, pp. 38378-38387 (2001).
Josef E. Herz, et al., “Fluorinated Sterols. Part II: 26,27—Polyfluorinated Desmosterols”,Journal of Fluorine Chemistry, vol. 8, pp. 209-222 (1976).
Mohammed N. Iqbal, et al., “Bile Acids. LXXXI. Synthesis and structural assignment of E/Z isomers of substituted methyl hydroxy-5β-cholest-24-en-26-oates”,Steroids, vol. 56, pp. 505-512 (Oct. 1991).
Janowski et al., “Structural Requirements of Ligands for the Oxysterol Liver X Receptor LXRα and LXRβ”, Proc. Natl. Acad. Sci. vol. 96, pp. 266-271, (Jan. 1999).
Kim et al., “Inhibitors of Sterol Synthesis, Chemical Synthesis, Structure, and Biological Activities of (25R)-3β,26-dihydroxy-5α-cholest-8(14)-en-15-one, a Metabolite of 3β-hydroxy-5α-cholest-8(14)-en-15-one”, Journal of Lipid Research 30:247-261, 1989.
Naoyuki Koizumi, et al., Synthesis of [25R]—and [25S]-25,26-Dihydroxyvitamin D31,Tetrahedron Letters, No. 32, pp. 2899-2902 (1978).
Kornel et al., “Studies on Steroid Conjugates: II Chemical Synthesis and Characterization of Sodium Cortisol-21-Sulfate and Sodium Tetrahydrocortisol-3, 21-Disulfate,” Steroids. P. 67-75 (1964).
Kurosawa et al., “Synthesis of 3α, 7α, 12α-trihydroxy-and 3α, 7α-dihydroxy-5β-cholestan-26-oic Acids by the Use of β-ketosulfoxide”, Steroids 60:439-444, 1995.
Bryan A. Laffitte, et al., “LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes”,PNAS, vol. 98, pp. 507-512, (Jun. 16, 2001).
Yvonne Lange, et al., “Cholesterol Movement in Niemann-Pick Type C Cells and in Cells Treated with Amphiphiles”,The Journal of Biological Chemistry, vol. 275, No. 23, pp. 17468-17475, (Jun. 9, 2000).
Dieter Leibfritz, et al., “Nuclear Magnetic Resonance Spectroscopy. Carbon-13 Spectra of Cholic Acids and Hydrocarbons Included in Sodium Desoxycholate Solutions”,Journal of American Chemical Society, vol. 95, No. 14, pp. 4996-5003 (Jul. 11, 1973).
Li et al., “Sterol Synthesis. Preparation and Characterization of Fluorinated and Deuterated Analogs of Oxygenated Derivatives of Cholesterol”, Chemistry and Physics of Lipids 99:33-71, 1999.
Nambara et al., “Preparation of Specific Antiserum to Estriol 3-Sulfate 16-Glucuronide,” Journal of Steroid Biochemistry, 21: p. 199-203 (1984).
S.H. Mujtaba Naqvi, “Chemical Synthesis and Mass Spectrometric Characterization of Some C-27 Steroids”,Steroids, vol. 22, pp. 285-290 (1973).
Roda et al., “Synthesis and Phsicochemical, Biological, and Pharmacological Properties of New Bile Acids Amidated with Cyclic Amino Acids”, J. Med. Chem. 39:2270-2276, 1996.
Ruelle et al., “The Mobile Order Solubility Equation Applied to Polyfunctional Molecules: The Non-hydroxysteroids in Aqueous and Non Aqueous solvents”, International Journal of Pharmaceutics 157:219-232, 1997.
Ching Song et al., “Auto-oxidized cholesterol sulfates are antagonistic ligands of liver X receptors: implications for the development and treatment of atherosclerosis”,Steroids, vol. 66, pp. 473-479 (2001).
Song et al., “Cholestenioc Acid Is a naturally Occuring Ligand for Liver X Receptor α,” Endocrinology, 141: p. 4180-4184 (2000).
Ching Song et al., “Hypolipidemic effects of selective liver X receptor alpha agonists”,Steroids, vol. 66, pp. 673-671 (2001).
Song et al., “Selective Activation of Liver X Receptor Alpha by 6α-Hydroxy Bile Acids and Analogs,” Steroids, 65: p. 423-427 (2000).
Song et al., “Ubiquitous Receptor: A Receptor that Modulates Gene Activation by Retinoic Acid and Thyroid Hormone Receptors”, Proc. Natl. Acad. Sci. 91:10809-10813, 1994.
Song et al., “Ubiquitous Receptor: Structures, Immunocytoche
Liao Shutsung
Song Ching
ARCH Development Corporation
Badio Barbara P.
Fish & Richardson P.C.
LandOfFree
Method of treating disorder related to high cholesterol... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating disorder related to high cholesterol..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating disorder related to high cholesterol... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3571067